The Peptide CommonsEst. May 2024
Independent. We sell nothing and are affiliated with no manufacturer or pharmacy. Every moderation action is logged in public
Topic summary

Second pass at: Reimbursement variation across member states

This is a generated summary. It shows the 5 most-liked posts from a topic of 29, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.
K
KTurkingtonTL3Regular11 Sep 2024#8

On post #4 — agreed on the reasoning, with one qualification.

An observation about Reimbursement variation across member states that I cannot explain and am posting anyway, on the principle that unexplained observations are more useful public than private.

21 likes 23mo
BA
b.aaltoTL220 Sep 2024#11
KTurkington, post #8: On post #4 — agreed on the reasoning, with one qualification. An observation about Reimbursement variation across member states that I cannot explain and am posting anyway, on the principle that unexplained observations are more useful public than private. Go to post

The public assessment report published at authorisation is one of the best free technical documents available on any of these compounds and it is rarely cited here.

That much is documented. The rest is how I have interpreted it.

22 likes in reply to #8 22mo
SC
s.cabreraTL210 Oct 2024#18

Post #15 is the version of this I will quote in future. One addition.

One caution on Reimbursement variation across member states: everything above assumes the underlying documentation is what it claims to be. That assumption is doing real work and is rarely stated.

31 likes 22mo
CS
c.serranoTL221 Oct 2024#22

Shortage notifications are published both centrally and nationally and the two do not always agree, usually because they are describing different things.

29 likes 21mo
K
KAnderssonTL3Regular7 Nov 2024#29

Post #27 is right about the mechanism and I think understates the practical bit.

Say which member state. A statement true in one is regularly false in another and the difference is not marginal.

Old habit: I write down the expected answer before I calculate it.

28 likes 21mo

Read the full topic (29 posts)

Suggested topics

TopicParticipantsRepliesViewsActivity
EMA product information as a primary source
Posting this under the heading it deserves: EMA product information as a primary source Everything below is what sits behind that. Something about EMA product information does not reconcile and I would like a…
YISVCDAMB+70 74 7k 8mo
German, French and Dutch differences, compared
German, French and Dutch differences, compared — setting out what I have, and where I think it stops being reliable. Asking about german directly, because I have read four threads on it and each answered a…
AKMMR 2 12k 10h
Cross-border purchase rules within the EU
On the subject in the title: Cross-border purchase rules within the EU Working notes rather than a conclusion. The question about cross-border purchase rules within that I actually want answered is the second…
HMEFVKGZA+45 49 15k 8mo
EMA product information as a primary source — does this still hold?
The question in the title: EMA product information as a primary source — does this still hold? I will give what I have already checked below so nobody repeats it. Something about EMA product information does…
CCSGRWIAII+127 150 41k 20mo
Revisiting: German, French and Dutch differences, compared
Posting this under the heading it deserves: Revisiting: German, French and Dutch differences, compared Everything below is what sits behind that. I have spent a fortnight trying to pin German down and I want…
ITKSTHEDS+90 99 32k 9mo

Related topics — sharing the tags personal import, formulary, cost per milligram

TopicParticipantsRepliesViewsActivity
Prescription requirements and telehealth models — a second dataset
On the subject in the title: Prescription requirements and telehealth models — a second dataset Working notes rather than a conclusion. Posting a small dataset on Prescription requirements and telehealth…
MOLAPFPHB+87 94 1.1k 21d
Tracking a shortage from primary sources rather than rumour — the long version
On the subject in the title: Tracking a shortage from primary sources rather than rumour — the long version Working notes rather than a conclusion. Tracking a shortage keeps being re-asked here and I think…
SDLSNM 2 60 1d
Price changes over 2025 and 2026, tabulated and dated — does this still hold?
Price changes over 2025 and 2026, tabulated and dated — does this still hold? I have a specific reason for asking rather than idle curiosity, and the context is below. Documenting an access outcome, dated,…
WMCCDFKSDO+147 156 18k 3mo
Reimbursement variation across member states
Reimbursement variation across member states Writing it up because I had to work it out twice and would rather nobody else did. Asking about reimbursement variation across member states directly, because I…
SFJSREBS+7 11 39k 3mo
Managing an unplanned gap in supply — what changed since
On the subject in the title: Managing an unplanned gap in supply — what changed since Working notes rather than a conclusion. What changes if the standard account of Managing an unplanned gap is wrong? I ask…
FEELIGRAC+114 124 54k 8mo